• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Nat Commun . BA.2 and BA.5 omicron differ immunologically from both BA.1 omicron and pre-omicron variants

tetano

Editor, Senior Moderator
Nat Commun


. 2022 Dec 13;13(1):7701.
doi: 10.1038/s41467-022-35312-3.
BA.2 and BA.5 omicron differ immunologically from both BA.1 omicron and pre-omicron variants


Annika Rössler[SUP] #[/SUP][SUP] 1 [/SUP], Antonia Netzl[SUP] #[/SUP][SUP] 2 [/SUP], Ludwig Knabl[SUP] 3 [/SUP], Helena Schäfer[SUP] 1 [/SUP], Samuel H Wilks[SUP] 2 [/SUP], David Bante[SUP] 1 [/SUP], Barbara Falkensammer[SUP] 1 [/SUP], Wegene Borena[SUP] 1 [/SUP], Dorothee von Laer[SUP] 1 [/SUP], Derek J Smith[SUP] 4 [/SUP], Janine Kimpel[SUP] 5 [/SUP]



Affiliations

Abstract

Several studies have shown that SARS-CoV-2 BA.1 omicron is an immune escape variant. Meanwhile, however, omicron BA.2 and BA.5 became dominant in many countries and replaced BA.1. As both have several mutations compared to BA.1, we analyzed whether BA.2 and BA.5 show further immune escape relative to BA.1. Here, we characterized neutralization profiles against the BA.2 and BA.5 omicron sub-variants in plasma samples from individuals with different history of exposures to infection/vaccination and found that unvaccinated individuals after a single exposure to BA.2 had limited cross-neutralizing antibodies to pre-omicron variants and to BA.1. Consequently, our antigenic map including all Variants of Concern and BA.1, BA.2 and BA.5 omicron sub-variants, showed that all omicron sub-variants are distinct to pre-omicron variants, but that the three omicron variants are also antigenically distinct from each other. The antibody landscapes illustrate that cross-neutralizing antibodies against the current antigenic space, as described in our maps, are generated only after three or more exposures to antigenically close variants but also after two exposures to antigenically distant variants. Here, we describe the antigenic space inhabited by the relevant SARS-CoV-2 variants, the understanding of which will have important implications for further vaccine strain adaptations.
 
Back
Top Bottom